EFG
NRXP icon

Ethos Financial Group’s NRX Pharmaceuticals NRXP Stock Holding History

Ethos Financial Group’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.9K Buy
15,900
+4,000
+34% +$8.07K ﹤0.01% 531
2025
Q4 		$32.2K Hold
11,900
– – ﹤0.01% 520
2025
Q3 		$39.3K Buy
+11,900
New +$34.1K ﹤0.01% 495

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Ethos Financial Group's NRXP Position: Q1 2026 in Review

Ethos Financial Group increased its NRX Pharmaceuticals (NRXP) stake by 34% in Q1 2026, buying an estimated $8.07K and bringing the position to 15,900 shares worth $33.9K. The position accounts for ﹤0.01% of the portfolio, ranked #531.

Ethos Financial Group first reported a position in NRXP in Q3 2025 and has held it in 3 quarters since. The position peaked at $39.3K in Q3 2025. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

  • Ethos Financial Group held 15,900 shares of NRX Pharmaceuticals worth $33.9K as of Q1 2026.
  • Ethos Financial Group bought 4,000 NRX Pharmaceuticals shares in Q1 2026, an estimated $8.07K.
  • NRX Pharmaceuticals made up ﹤0.01% of Ethos Financial Group's portfolio in Q1 2026, its #531 holding.
  • Ethos Financial Group first reported a position in NRX Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Ethos Financial Group's NRX Pharmaceuticals position peaked at $39.3K in Q3 2025.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Ethos Financial Group's 13F filing for Q1 2026, filed 5 May 2026.